Genetic Technologies Debt to Equity Ratio 2006-2021 | GENE

Current and historical debt to equity ratio values for Genetic Technologies (GENE) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Genetic Technologies debt/equity for the three months ending June 30, 2021 was 0.00.
Genetic Technologies Debt/Equity Ratio Historical Data
Date Long Term Debt Shareholder's Equity Debt to Equity Ratio
2021-06-30 $0.00B $0.02B 0.07
2020-12-31 $0.00B $0.01B 0.08
2020-06-30 $0.00B $0.01B 0.20
2019-12-31 $0.00B $0.00B 0.52
2019-06-30 $0.00B $0.00B 0.84
2018-12-31 $0.00B $0.00B 0.36
2018-06-30 $0.00B $0.00B 0.31
2017-12-31 $0.00B $0.01B 0.17
2017-06-30 $0.00B $0.01B 0.15
2016-12-31 $0.00B $0.01B 0.12
2016-06-30 $0.00B $0.01B 0.12
2015-12-31 $0.00B $0.01B 0.08
2015-06-30 $0.00B $0.02B 0.09
2014-12-31 $0.00B $0.00B 10.76
2014-06-30 $0.01B $0.00B 2.70
2013-12-31 $0.01B $0.01B 1.09
2013-06-30 $0.00B $0.01B 0.45
2012-12-31 $0.00B $0.01B 0.17
2012-06-30 $0.00B $0.02B 0.14
2011-12-31 $0.00B $0.02B 0.11
2011-06-30 $0.00B $0.01B 0.31
2010-12-31 $0.00B $0.01B 0.24
2010-06-30 $0.00B $0.01B 0.50
2009-12-31 $0.00B $0.01B 0.29
2009-06-30 $0.00B $0.01B 0.29
2008-12-31 $0.00B $0.01B 0.19
2008-06-30 $0.00B $0.02B 0.17
2007-12-31 $0.00B $0.02B 0.11
2007-06-30 $0.00B $0.01B 0.25
2006-12-31 $0.00B $0.02B 0.16
2006-06-30 $0.00B $0.03B 0.12
2005-12-31 $0.00B $0.03B 0.11
2005-06-30 $0.01B $0.02B 0.30
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.037B $0.000B
Genetic Technologies was the first company in the world to recognize important new applications for `non-coding` DNA (DeoxyriboNucleic Acid). The Company has since been granted patents securing intellectual property rights for particular uses of non-coding DNA in genetic analysis and gene mapping across all genes in all multicellular species.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $125.477B 7.93
Bio-Rad Laboratories (BIO.B) United States $23.034B 46.74
QIAGEN (QGEN) Netherlands $12.874B 21.80
Biohaven Pharmaceutical Holding (BHVN) United States $7.457B 0.00
Arcus Biosciences (RCUS) United States $3.257B 0.00
Emergent Biosolutions (EBS) United States $2.378B 8.55
Myovant Sciences (MYOV) United Kingdom $1.780B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.529B 0.00
Zymeworks (ZYME) Canada $0.908B 0.00
Ambrx Biopharma (AMAM) United States $0.407B 0.00
SQZ Biotechnologies (SQZ) United States $0.345B 0.00
Enzo Biochem (ENZ) United States $0.164B 16.09